Voyager Therapeutics Company Profile

11:50 EDT 18th June 2018 | BioPortfolio

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to advancing the field of AAV (adeno-associated virus) gene therapy through innovation and investment in vector optimization and engineering, dosing techniques, as well as process development and production. The company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis (ALS), and Friedreich’s ataxia. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics was launched in 2014 with funding from leading life sciences investor Third Rock Ventures and is headquartered in Cambridge, Mass. For more information, please visit

News Articles [832 Associated News Articles listed on BioPortfolio]

Quotidian Technical Highlights on Selected Biotech Stocks -- Voyager Therapeutics, Cambrex, ... Voyager Therapeutics Cambridge, Massachusettsheadquartered Voyager Therapeutics Inc.'s shares recorded a trading volume of 212,557 shares last Friday. The stock...

AbbVie and Voyager Therapeutics Launch $1.2 Billion+ Alzheimer’s Partnership

AbbVie and Voyager Therapeutics inked a collaboration deal to develop treatments for Alzheimer’s disease and other neurodegenerative diseases.

AbbVie And Voyager Therapeutics To Collaborate On New Alzheimer's Treatments

NewsVoyager to receive $69 million upfront payment and potentially up to $155 million in preclinical and Phase 1 option payments as well as development and regulatory milestone payments and royalties.

Voyager's advanced Parkinson's disease therapy IND approved by FDA

The FDA approved Voyager Therapeutics' investigational new drug application for VY-AADC, which is being developed as a treatm -More- 

Active-Investors: Wired News - Voyager Therapeutics Signs Global Collaboration Agreement with AbbVie to Develop New Treatments for Tau-Related Neuro-Degenerative Diseases

Stock Monitor: Bioverativ Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 22, 2018 / has just released a free research report on Voyager Therapeutics, Inc. (NASDAQ: ...

AbbVie and Voyager Therapeutics collaborate to develop new treatments for tauopathies

AbbVie, a global biopharmaceutical company, and Voyager Therapeutics, Inc., a clinical-stage gene therapy company, today announced that they have entered into an exclusive strategic collaboration and ...

Investor Network: Voyager Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 14, 2018 / Voyager Therapeutics, Inc. (NASDAQ: VYGR) will be discussing their earnings results in their Q4 Earnings Call to be held on March 14, 2018, at 8:00 AM E...

With $69M Deal, AbbVie Turns to Voyager for an Alzheimer’s Gene Therapy

At a time when uncertainty again swirls around the development of Alzheimer’s disease drugs, research continues in new ways. Through an alliance this morning, Voyager Therapeutics will team with Abb...

PubMed Articles [415 Associated PubMed Articles listed on BioPortfolio]

Günter Blobel: a voyager of the cell.

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Recent developments in intracellular protein delivery.

Protein therapeutics based on transcription factors, gene editing enzymes, signaling proteins and protein antigens, have the potential to provide cures for a wide number of untreatable diseases, but c...

Alternative therapeutics for self-limiting infections-An indirect approach to the antibiotic resistance challenge.

Alternative therapeutics for infectious diseases is a top priority, but what infections should be the primary targets? At present there is a focus on therapies for severe infections, for which effecti...

Eyes on New Product Development: Preclinical Research.

Clinical Trials [149 Associated Clinical Trials listed on BioPortfolio]

Nativis Voyager for Newly Diagnosed GBM

This feasibility study will assess the effects of the Nativis Voyager therapy in patients newly diagnosed with GBM. The study will enroll and treat up to 11 subjects and will be combined w...

A Feasibility Study of the Nativis Voyager™ System in Patients With Recurrent Glioblastoma Multiforme (GBM) in Australia

This feasibility study will assess the effects of the Nativis Voyager therapy in patients with recurrent GBM who have either failed standard of care or are intolerant to therapy. The study...

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

Companies [1242 Associated Companies listed on BioPortfolio]

Voyager Therapeutics, Inc.

Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system. Voyager is committed to advanc...

Voyager Therapeutics

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). Voyager is committed to...

Voyager Pharmaceutical Corp.

Voyager Pharmaceutical Corporation MissionVoyager Pharmaceutical Corporation embraces bold ideas and novel approaches to achieve…Cures for Mankind. Challenges & Rewards for every member of our team....

Yardi Systems

Yardi Systems has been committed to the design, development, and support of innovative software solutions for nearly 30 years. With the products comprising its Yardi Voyage...

Yardi Systems Inc.

Yardi Systems has been committed to the design, development and support of innovative software solutions for 30 years. With its senior housing software and investment management s...

More Information about "Voyager Therapeutics" on BioPortfolio

We have published hundreds of Voyager Therapeutics news stories on BioPortfolio along with dozens of Voyager Therapeutics Clinical Trials and PubMed Articles about Voyager Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Voyager Therapeutics Companies in our database. You can also find out about relevant Voyager Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Corporate Database Quicklinks

Searches Linking to this Company Record